KIF20A and melanoma: Additionally, the AUC for KIF20A in predicting response to PD-1 inhibitors was higher than for CD274 and PDCD1 (Figure 7F), a finding confirmed in another cohort of 28 melanoma patients undergoing anti-PD-1 checkpoint inhibition therapy (Figure 7G).